![](https://webarchive.library.unt.edu/web/20090509202401im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/web/20090509202401im_/http://www.cancer.gov/images/spacer.gif)
tandutinib A piperazinyl quinazoline receptor tyrosine kinase inhibitor with antineoplastic activity. Tandutinib inhibits the autophosphorylation of FLT3 (FMS-Like Tyrosine kinase-3), c-KIT and PDGF (platelet-derived growth factor) receptor tyrosine kinases, thereby inhibiting cellular proliferation and inducing apoptosis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/web/20090509202401im_/http://www.cancer.gov/images/spacer.gif)
Code names: | ![](https://webarchive.library.unt.edu/web/20090509202401im_/http://www.cancer.gov/images/spacer.gif) | CT53518 MLN518 | | ![](https://webarchive.library.unt.edu/web/20090509202401im_/http://www.cancer.gov/images/spacer.gif) | Chemical structure name: | ![](https://webarchive.library.unt.edu/web/20090509202401im_/http://www.cancer.gov/images/spacer.gif) | 1-piperazinecarboxamide, 4-[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]-N-[4-(1-methylethoxy)phenyl]- | | ![](https://webarchive.library.unt.edu/web/20090509202401im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20090509202401im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/web/20090509202401im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/web/20090509202401im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/web/20090509202401im_/http://www.cancer.gov/images/spacer.gif) |